Lilly says retatrutide meets endpoints in two Phase 3 obesity trials, plans FDA filing in Q1 2027

Reuters2026/07/23 10:52

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Eli Lilly reported positive topline results from two Phase 3 trials of retatrutide, supporting planned global filings for an obesity indication.
TRIUMPH-2 showed up to 20.8% average weight loss at 80 weeks in adults with obesity or overweight with type 2 diabetes; A1C fell up to 1.6%.
TRIUMPH-3 showed up to 22.6% average weight loss at 80 weeks in adults with severe obesity with established cardiovascular disease.
FDA submission planned as a Biologics License Application in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lilly says retatrutide meets endpoints in two Phase 3 obesity trials, plans FDA filing in Q1 2027

You may also like

Crypto prices